Skip to main content
. 2020 Jul 9;12(13):13518–13528. doi: 10.18632/aging.103458

Table 5. Correlations between miRNA-29s and clinical characteristics of patients with Parkinson’s disease.

miRNA-29a## miRNA-29b## miRNA-29c
r p value r p value r p value
Age, years 0.117 0.251 0.122 0.233 0.114 0.262
Gender## -0.059 0.567 -0.084 0.411 -0.008 0.940
Education, years 0.000 0.998 -0.003 0.975 -0.031 0.768
Disease duration, months## 0.047 0.664 -0.113 0.292 0.049 0.648
UPDRS-III subscore -0.097 0.350 -0.087 0.403 0.024 0.817
Hoehn and Yahr stage## -0.029 0.776 -0.023 0.828 0.111 0.280
ESS score## 0.094 0.364 0.003 0.975 0.109 0.292
GDS score -0.124 0.234 -0070 0.502 -0.039 0.707
SSST 12 score -0.025 0.811 0.027 0.798 -0.015 0.882
RBDSQ score 0.058 0.587 0.031 0.768 0.077 0.468
Hallucination## -0.098 0.338 0.016 0.878 -0.080 0.437
LED (mg/day)## -0.043 0.713 -0.109 0.344 0.195 0.090

P values correspond to correlation between miRNA-29s and clinical characteristics.

Abbreviations: UPDRS, Unified Parkinson’s Disease Rating Scale. ESS, Epworth Sleepiness Scale. GDS, Geriatric Depression Scale. SSST 12, the Sniffin’ Sticks Screening 12 Test. RBDSQ, Rapid Eye Movement Sleep Behavior Disorder Screening Questionnaire. LED, Levodopa equivalent dose.

#Off-state motor ratings according to the UPDRS (motor section).

## P values correspond to spearman correlation test for unnormal-distributed data.